Infection

Siemens Zika test receives FDA emergency use authorization

The U.S. Food and Drug Administration (FDA) has granted Siemens Healthcare Diagnostics Inc. (Siemens) an Emergency Use Authorization (EUA) for its real-time PCR Zika Virus assay, the VERSANT® Zika RNA 1.0 Assay (kPCR) Kit. With respect to Zika in vitro diagnostic tests, FDA has been authorized to issue EUAs to allow for use of unapproved medical products or unapproved uses of approved medical products when, among other circumstances, there are no adequate, approved, and available alternatives and certain additional criteria are met.

Photo: Siemens Zika test receives FDA emergency use authorization

“The FDA’s emergency use authorization of the VERSANT® Zika RNA 1.0 Assay (kPCR) Kit from Siemens can lead us one step closer to stopping the spread of the Zika virus,” says Fernando Beils, Vice President, Head of Molecular Diagnostics, Siemens . “Being able to quickly diagnose patients will help physicians to more efficiently manage those affected.”

The VERSANT® Zika RNA 1.0 Assay (kPCR) Kit is capable of detecting the presence of Zika virus, which can be an earlier indicator of Zika virus infection than anti-Zika antibodies. The molecular test is validated for plasma, serum, and urine (collected alongside a patient-matched serum or plasma specimen) from individuals meeting CDC Zika virus clinical criteria and/or CDC Zika virus epidemiological criteria, and is designed to run on the Siemens VERSANT® kPCR Sample Prep automated platform, along with several commercially available thermal cyclers. The assay must be run by laboratories in the United States that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests, or by similarly qualified non-U.S. laboratories. The VERSANT® Zika RNA 1.0 Assay (kPCR) Kit has not been FDA cleared or approved and is only authorized for use for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection.
 
Click here for more information on the FDA’s EUA for Siemens’ VERSANT Zika RNA 1.0 Assay (kPCR).


[i] http://www.fda.gov/EmergencyPreparedness/Counterterrorism/ucm182568.htm

Source: Siemens Healthcare Diagnostics

02.08.2016

Read all latest stories

Related articles

Photo

Siemens Healthineers and Flywheel

Partnership for healthcare research collaboration

Medical data management company Flywheel announced a partnership and enterprise license agreement with Siemens Healthineers. Under the agreement, Flywheel will deliver a cloud-based research…

Photo

How to deliver more and better care at lower costs

Moving the needle in MRI productivity

In an industry where every second and every click counts, workflow inefficiencies consume as much as a third of the MRI procedure time. This is a key area of focus where technology advances can…

Photo

The most compact .55-T full body scanner

Lungs plus A&E MRI scans – no problem

Low, light and with a field strength: 0.55-tesla with added new digital technologies. Indeed, this is a very new class of MRI scanner created by Siemens Healthineers. We interviewed Christiane…

Related products

Subscribe to Newsletter